Novo Nordisk denied interim stay in Indian semaglutide patent appeal
Novo Nordisk failed to secure interim relief before an Indian court, allowing Dr. Reddy’s Laboratories to continue manufacturing and exporting semaglutide amid a credible challenge to patent validity. In a setback...To view the full article, register now.
Already a subscriber? Click here to view full article